Holen Sie sich die Stockscreener-App
2.85
9.20%
0.24
Handel nachbörslich:
2.80
-0.05
-1.75%
Schlusskurs vom Vortag:
$2.61
Offen:
$2.61
24-Stunden-Volumen:
5,888
Relative Volume:
1.27
Marktkapitalisierung:
$16.46M
Einnahmen:
Nettoeinkommen (Verlust:
$-2.17M
KGV:
-0.1643
EPS:
-17.3434
Netto-Cashflow:
$-4.82M
1W Leistung:
-8.36%
1M Leistung:
-14.16%
6M Leistung:
+14.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.61
$2.90
1-Wochen-Bereich:
$2.61
$3.2787
52-Wochen-Spanne:
$1.8299
$7.64
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
2.85 | 16.46M | 0 | -2.17M | -4.82M | -17.34 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Newcelx Ltd Aktie (NCEL) Neueste Nachrichten
Positive Signs As Multiple Insiders Buy NewcelX Stock - Simply Wall Street
NewcelX (Nasdaq: NCEL) outlines $25M share deal with Alpha - Stock Titan
NewcelX (NASDAQ: NCEL) warns on cash as diabetes trial plans advance - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com
NewcelX Ltd (NCEL) Slides 2.87% to $3.38, Approaches Key Support at $3.21Mean Reversion Trade - siam.in
NewcelX (NCEL) Latest: Moves 3.18% Down to $3.26 in the Latest Session; the Near-Term Reference Band Stretches From $3.10 to $3.42 in Latest TradingPut Dominated - vinanet.vn
NewcelX (NCEL) Latest: Moves 3.18% Down to $3.26 in the Latest Session; the Near-Term Reference Band Stretches From $3.10 to $3.42 in Latest TradingHot Stock Picks - dars.gov.et
NewcelX Ltd (NCEL) Shareholders to Sell 694,000 Shares Amid Unpr - GuruFocus
NewcelX Ltd (NCEL) Pulls Back 2.54% as Shares Test Near-Term Support at $3.10Wyckoff Upthrust - vinanet.vn
NewcelX Ltd (NCEL) Pulls Back 2.54% as Shares Test Near-Term Support at $3.10Bullish Sentiment - dars.gov.et
NewcelX Ltd (NCEL) Pulls Back 2.54% as Shares Test Near-Term Support at $3.10Composite Profile - dars.gov.et
NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewcelX (NCEL) Slides 6.2% to $3.34, Testing Key Support Near $3.17Diagonal Spread Trade - vinanet.vn
NewcelX Lines Up $1.4 Million Private Placement to Advance Type 1 Diabetes Program - theglobeandmail.com
NewcelX Ltd. (NCEL) Rises 3.83% to $3.49, Testing Key Resistance at $3.66Death Cross - vinanet.vn
Press Release: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing - Moomoo
NewcelX Announces $1.4 Million Private Placement at 20% Premium to Market to Advance NCEL-101 for Type 1 Diabetes - Quiver Quantitative
NewcelX Prices $1.4 Million Premium Equity Financing to Advance Type 1 Diabetes Cell Therapy - TipRanks
NewcelX Ltd. (NCEL) Edges Higher as Stock Tests Key Resistance at $3.70Post-Earnings Moves - dars.gov.et
NewcelX Ltd. (NCEL) Edges Higher as Stock Tests Key Resistance at $3.70Retail Volume - vinanet.vn
NewcelX Ord Shs (NCEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewcelX Ord Shs (NCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NewcelX Ord Shs (NCEL) Income Statement - TradingKey
NewcelX Ord Shs (NCEL) Balance Sheet - TradingKey
NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewcelX Ord Shs (NCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewcelX Ord Shs (NCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewcelX Ord Shs (NCEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey
NewcelX Ord Shs (NCEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey
NewcelX Ord Shs (NCEL) Cash Flow - TradingKey
NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey
NewcelX Ltd. Revenue Breakdown – NASDAQ:NCEL - TradingView
NewcelX (NCEL) Secures Patent for Innovative Technology - GuruFocus
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio - The Manila Times
NewcelX Ltd. (NCEL) Holds Near $3.98 Support Zone After Modest DeclineRip Sell Trade - dars.gov.et
NewcelX Ltd. (NCEL) Holds Near $3.98 Support Zone After Modest DeclineAAII Bearish - dars.gov.et
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com Nigeria
Laidlaw Initiates NewcelX(NCEL.US) With Buy Rating, Announces Target Price $23 - Moomoo
NCEL Initiated Coverage by Laidlaw & Co. -- Price Target Announced at $23 - GuruFocus
Laidlaw initiates NewcelX stock with buy rating on diabetes therapy - Investing.com
NLSP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com South Africa
NewcelX Strengthens Diabetes Push With Appointment of Leading Transplant Pioneer Camillo Ricordi - TipRanks
NewcelX appoints diabetes researcher Ricordi to advisory board - Investing.com
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board - The Manila Times
NewcelX appoints diabetes research pioneer Dr. Camillo Ricordi to boost Type 1 diabetes therapy development. - Pluang
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com Canada
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com UK
Finanzdaten der Newcelx Ltd-Aktie (NCEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Newcelx Ltd-Aktie (NCEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Revel Michel | CSO and Director |
Apr 27 '26 |
Buy |
2.75 |
54,545 |
149,999 |
957,530 |
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):